Dr Reddy's gets nod to roll out generic oral semaglutide drug

"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to Novo Nordisk's oral semaglutide (Rybelsus brand). Based on this clinical evidence, our product has received regulatory approval in India under the biosimilar regulatory pathway," a company spokesperson said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ni8MIN3
via IFTTT